Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety

NCT01908322 · clinicaltrials.gov ↗

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)

Sponsor

Bayer